Arvinas is a clinical-stage biotechnology company that has developed an induced protein degradation strategy to recruit targeted proteins for ubiquitination and subsequent proteasome-mediated degradation. The technology, called Proteolysis Targeting Chimeras (PROTACs), shows great potential in harnessing the action of a single E3 ligase toward pathologically important proteins that are currently undruggable . . .
